ALREX has a low incidence of elevated IOP1†

In clinical studies, patients treated with ALREX presented similar rates of intraocular pressure (IOP) elevation as placebo.1*†

  • Incidence of clinically significant increases in IOP (≥10 mm Hg) was 1% with ALREX and 1% with placebo in two 6-week safety and efficacy trials in patients with seasonal allergic conjunctivitis (SAC).

*Study design: Two 6-week, double-masked, placebo-controlled, multicenter environmental studies conducted during pollen season in which patients (N=268) with moderate to severe signs and symptoms of SAC bilaterally received ALREX (0.2%) or placebo QID for 42 days. Primary efficacy variables were bulbar conjunctival injection (signs) and ocular itching (symptoms) resolution at Day 14.

†If ALREX is used for more than 10 days, IOP should be monitored.

REGISTER FOR UPDATES

Get additional information and resources.

Sign up now

LEARN ABOUT THE PHARMACOLOGY OF ALREX

See how ocular corticosteroids work.

Get the details
 
Indication

ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Important Safety Information
  • ALREX is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. ALREX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
  • Prolonged use of ALREX is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.
  • If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
  • Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.

Click here for Prescribing Information for ALREX.

Reference: 1. ALREX [package insert]. Tampa, FL: Bausch & Lomb Incorporated; May 2016.

Indication

ALREX® (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis.

Important Safety Information
  • ALREX is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular structures. ALREX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
  • Prolonged use of ALREX is associated with several warnings and precautions, including glaucoma with optic nerve damage, defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular infections (including herpes simplex), delay in wound healing and increase in bleb formation.
  • If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
  • Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% - 0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia.

Click here for Prescribing Information for ALREX.

THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.

Please choose an option below:

I am a healthcare professional
in the U.S.
I am not a
healthcare professional